Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.30 |
| ▸ | BAD | Q92934 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366297 | 0.91 | TDP1 (0.39) | TDP1NOTUMAKR1B1MAPK14ALDH1A1 | |
| SCHEMBL12366287 | 0.88 | PARP1 (0.37) | MAPK14ALDH1A1MAPK1 | |
| SCHEMBL12366629 | 0.86 | SLC9A1 (0.37) | — | |
| SCHEMBL12366293 | 0.85 | TDP1 (0.39) | TDP1ALDH1A1MAPK1 | |
| SCHEMBL12366145 | 0.85 | TDP1 (0.40) | TDP1NOTUMAKR1B1MAPK14ALDH1A1 | |
| SCHEMBL12366273 | 0.84 | TDP1 (0.39) | TDP1AKR1B1MAPK14ALDH1A1 | |
| SCHEMBL12365914 | 0.82 | KDM4A (0.40) | TDP1AKR1B1MAPK14ALDH1A1MAPK1 | |
| SCHEMBL12366309 | 0.81 | TDP1 (0.39) | TDP1AKR1B1MAPK14ALDH1A1 | |
| SCHEMBL12389148 | 0.81 | LMNA (0.46) | TDP1MAPK1 | |
| SCHEMBL12366177 | 0.81 | TDP1 (0.39) | TDP1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | TDP1 378/4885NOTUM 1719/4885AKR1B1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.